EP1572191A1 - Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings - Google Patents

Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings

Info

Publication number
EP1572191A1
EP1572191A1 EP02781652A EP02781652A EP1572191A1 EP 1572191 A1 EP1572191 A1 EP 1572191A1 EP 02781652 A EP02781652 A EP 02781652A EP 02781652 A EP02781652 A EP 02781652A EP 1572191 A1 EP1572191 A1 EP 1572191A1
Authority
EP
European Patent Office
Prior art keywords
brevifoliol
pharmaceutically acceptable
acceptable carrier
formula
chemotherapeutic treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02781652A
Other languages
German (de)
French (fr)
Inventor
S.P.S. Central Ins. Med. & Arom. Plants KHANUJA
RSK C. Ins. Med. & Arom. Plants TIRUPADIRIPULIYUR
A. Central Ins. Med. & Arom. Plants GARG
R.K. Central Ins. Med. & Arom. Plants MISHRA
SK Central Ins. Med. & Arom. Plants CHATTOPADHYAY
S. Central Ins. Med. & Arom. Plants SRIVASTAVA
A.S. Central Ins. Med. & Arom. Plants NEGI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Council of Scientific and Industrial Research
Original Assignee
Council of Scientific and Industrial Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council of Scientific and Industrial Research filed Critical Council of Scientific and Industrial Research
Priority claimed from PCT/IB2002/005399 external-priority patent/WO2004054569A1/en
Publication of EP1572191A1 publication Critical patent/EP1572191A1/en
Withdrawn legal-status Critical Current

Links

Definitions

  • the present invention relates to a method for the chemotherapeutic treatment of human beings using brevifoliol. More particularly, the present invention relates to the use of brevifoliol for the treatment human cancer lines. The present invention also relates to the bioactivity testing of taxanes from the leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in- vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer in humans. The present invention also relates to a pharmaceutical composition containing brevifoliol and a pharmaceutically acceptable carrier for the chemotherapeutic treatment of human beings.
  • Taxus brevifolia Nutt. was described by Wani M.C. et al (in 1971, J.Am.Chem.Soc. 93, 2325- 2327).
  • This compound named taxol (also known in the literature as paclitaxel) demonstrated moderate in vivo activity against the P-388, P-1534, and L-1210 murine leukaemia, the Walker 256 carcino-sarcoma, sarcoma 180, and Lewis lung tumor test systems. Taxol has a wide spectrum of anticancer activity. It has been approved by the Food and Drug Administration of United States in 1992 for the treatment of ovarian cancer and again in 1994 for the treatment of breast cancers.
  • taxol has garnered support as an anticancer agent, culminating in recent FDA approval of its use against breast and ovarian cancers.
  • Taxol shows promise against refractory breast and ovarian cancers, which are difficult to treat and which are responsible for the deaths of 60,000 women every year (Chemical &Engineering News 1991, (Sept.), 11-18).
  • antimicrotubule agents which block microtubule production, taxol promotes tubulin polymerisation and stabilizes microtubules against depolymerization (Schiff P.B., et al. 1979, Nature 277, 665-667).
  • Microtubules are important subcellular target for chemotherapeutic agents.
  • Antimicrotubule agents including the Ninca (Catharanthus) alkaloids, are extremely potent, requiring only a few molecules to disrupt the microtubular structure of cancer cells. The discovery of a new compound targeting these structures is of particular importance.
  • Himalayan yew has a remarkable history of medicinal uses.
  • the leaves of the Himalayan yew are used for treatment of hysteria, epilepsy, nervousness and as a lithic in calculus complaints while its non-poisonous fleshy arils have carminative, expectorant and stomachic properties (The Wealth of India (1976), p.132-134).
  • Himalayan yew (Taxus wallichiana) also contains the potent anticancer drug taxol and its important precursor 10-deacetyl baccatin III (DAB).
  • the aim of present invention was to isolate different types of taxanes other than taxol, from the leaves commonly called 'needles' of Taxus wallichiana and evaluate their anticancer potential.
  • a taxane brevifoliol [1] was identified which showed promising anticancer activity against in- vitro grown human cancer cell lines.
  • the main object of the invention is to provide a composition for the chemotherapeutic treatment of human beings.
  • the present invention provides bioactivity testing of various taxanes isolated from leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in- vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer such as ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells where the IC90 values are comparatively similar or even less than that of standard drug 'taxol'.
  • Brevifoliol is used as a cancer chemotherapeutic agent.
  • the present invention provides a composition for chemotherapeutic treatment of human beings, comprising a pharmaceutically effective amount of brevifoliol of the formula 1 and a pharmaceutically acceptable carrier.
  • the amount of brevifoliol is in the range of 0.004 to 20 ⁇ g/ml.
  • the present invention also provides a method for the chemotherapeutic treatment of human beings comprising administering to a patient suffering from cancer, a therapeutically effective amount of brevifoliol of the formula 1
  • Formula 1 along with a pharmaceutically acceptable carrier.
  • the concentration of brevifoliol is in the range of 0.004 to 20 ⁇ g/ml.
  • the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
  • the chemotherapeutic treatment is limited to ovarian, colon, breast and oral cancers.
  • the invention also provides a method for treatment of human cancer lines comprising administering to a patient a therapeutically effective amount of brevifoliol of the formula 1
  • Formula 1 along with a pharmaceutically acceptable carrier.
  • the concentration of brevifoliol is in the range of 0.004 to 20 ⁇ g/ml.
  • the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
  • the human cancer lines are selected from the group consisting of ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells.
  • the present invention also provides for the use of brevifoliol of the formula 1
  • Formula 1 along with a pharmaceutically acceptable carrier for the chemotherapeutic treatment of human beings.
  • the concentration of brevifoliol is in the range of 0.004 to 20 ⁇ g/ml.
  • the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
  • the chemotherapeutic treatment is limited to ovarian, colon, breast and oral cancers.
  • the invention also provides for the use of brevifoliol of formula 1
  • Formula 1 along with a pharmaceutically acceptable carrier for chemotherapeutic treatment of human beings.
  • the concentration of brevifoliol is in the range of 0.004 to 20 ⁇ g/ml.
  • the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
  • the human cancer lines are selected from the group consisting of ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells. Detailed description of the invention
  • the IC 90 data obtained by the MTT assay may overestimate the cell killing activity of a compound.
  • the clonogenic assay for tumor cells which determines the actual cell death was performed to determine the cytotoxic potential of test compounds.
  • Persons skilled in the art of anti-cancer drug discovery can perform both these assays.
  • brevifoliol was highly inhibitory to ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells where the IC90 values were comparatively similar or even less than that of standard drug 'taxol'.
  • PA-1 ovarian
  • Caco-2 colon
  • MCF-7 breast
  • KB-403 oral cancer cells where the IC90 values were comparatively similar or even less than that of standard drug 'taxol'.
  • brevifoliol can be used as cancer chemotherapeutic agent.
  • Brevifoliol was first isolated from the leaves (also referred as 'needles') of the plant Taxus brevifolia (Baka et al Phytochemistry 30, p.1613-1614; 1991). The process of its isolation involved extracting the fresh leaves of Taxus wallichiana with ethyl alcohol to get an extract. The crude extract after concentration was diluted with water and partitioned between hexane, chloroform and ethyl acetate sequentially. The chloroform extract upon concentration yielded a dark brown residue. The resultant residue was subjected to column chromatography over silica gel and eluted with chloroform and chloroform-methanol gradient. Six fractions were collected and brevifoliol was isolated from fraction five by rechromatography over silica gel and eluting with hexane-ethyl acetate gradient.
  • Brevifoliol has been isolated from other species of Taxus including the Himalayan yew tree Taxus wallichiana that is available in India. Recently, the structure of brevifoliol has been revised and it was shown to belong to 11 (15-1) abeo taxoid bicyclic skeleton of formula [1].
  • brevifoliol was also isolated from the leaves of the plant following a process which involved extracting the dried and crushed needles of Taxus wallichiana with methanol for 72 hours and the extract was concentrated in vacuo. The concentrate was diluted with water and extracted with hexane and chloroform respectively. Concentration of the chloroform phase under vacuum left a residue, which was separated by column chromatography over silica gel.
  • Cytotoxicity testing in vitro was done by the method of Woerdenbag et al.,1993; J.NatProd. 56 (6): 849-856). 2x10 3 cells/well were incubated in the 5% CO 2 incubator for 24h to enable them to adhere properly to the 96 well polysterene microplate (Grenier, Germany). Test compounds dissolved in 100% DMSO (Merck,Germany) in at least five doses were added and left for 6h after which the compound plus media was replaced with fresh media and the cells were incubated for another 48h in the CO 2 incubator at 37°C. The concentration of DMSO used in our experiments never exceeded 1.25%, which was found to be non-toxic to cells.
  • IC 90 is the concentration ⁇ g/mL required for 90% inhibition of cell growth as compared to that of untreated control.
  • the results described in Table 2 indicate that brevifoliol is active against all cancer cell lines except liver cancer (WRL-68).
  • Table 2 Cytotoxic properties (IC 90 in ⁇ g/mL) of various taxanes isolated from T.wallichiana against human cancer cells.
  • the clonogenic assay for tumor cells which determines the actual cell death was performed to determine the cytotoxic potential of test compounds.
  • the principle of clonogenic assay is to investigate the ability of an individual cell to form a colony on a soft agar plate containing various concentrations of test compounds.
  • IC 90 concentration of test compound resulting in 90 % of the control (untreated) colonies was denoted as IC 90 and was used as a parameter for cytotoxicity.
  • the assay was performed as described previously except that the test compounds were added into the top soft agar and the cells were plated out to form colonies.
  • Anthracycline derivative doxorubiciti and microtubule depolymerization inhibitor paclitaxel both established anticancer agents were included as standard reference drugs.
  • Table 3 Cytotoxic properties (IC 90 in ⁇ g/mL) of various taxanes isolated from T.wallichiana against human cancer cells.
  • Brevifoliol was crystallized from petroleum ether-acetone mixture as needles. Brevifoliol, mp 200-201°C, ]D -25°C (C 1, MeOH) was characterized on the basis of its reported spectral data and by direct comparison with an authentic sample (Chattopadhyay, S.K. et al , Indian J. Chemistry 35B, 175-177 (1996)). The reaction mechanism is given below:

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the bioactivity of taxanes isolated from the leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in-vitro and subsequent identification of brevifoliol (1) as anticancer agent useful in the treatment of various types of cancer in humans.

Description

PHARMACEUTICAL COMPOSITION CONTAINING BREVIFOLIOL FOR USE IN CHEMOTHERAPEUTIC TREATMENT OF HUMAN BEINGS
Field of the invention
The present invention relates to a method for the chemotherapeutic treatment of human beings using brevifoliol. More particularly, the present invention relates to the use of brevifoliol for the treatment human cancer lines. The present invention also relates to the bioactivity testing of taxanes from the leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in- vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer in humans. The present invention also relates to a pharmaceutical composition containing brevifoliol and a pharmaceutically acceptable carrier for the chemotherapeutic treatment of human beings.
(1) Background of the invention
In 1971, a novel compound isolated from the bark of the northwest Pacific yew tree, Taxus brevifolia Nutt. was described by Wani M.C. et al (in 1971, J.Am.Chem.Soc. 93, 2325- 2327). This compound, named taxol (also known in the literature as paclitaxel) demonstrated moderate in vivo activity against the P-388, P-1534, and L-1210 murine leukaemia, the Walker 256 carcino-sarcoma, sarcoma 180, and Lewis lung tumor test systems. Taxol has a wide spectrum of anticancer activity. It has been approved by the Food and Drug Administration of United States in 1992 for the treatment of ovarian cancer and again in 1994 for the treatment of breast cancers. It has also been found to be effective against leukemia, and cancer of the head, neck, endometrium and lungs. Recently, it has also been used to treat polycystic kidney disease which accounts for ten percent of the kidney transplant among the dialysis patients (Nature p.750, 1994).
In more than twenty years since the initial report of its isolation, structure elucidation, and bioactivity, taxol has garnered support as an anticancer agent, culminating in recent FDA approval of its use against breast and ovarian cancers. There are two main reasons for the attention directed toward this drug. First, it shows promise against refractory breast and ovarian cancers, which are difficult to treat and which are responsible for the deaths of 60,000 women every year (Chemical &Engineering News 1991, (Sept.), 11-18). Second, it exhibits a mode of action, which is unique among cancer chemotherapeutic agents. Unlike known antimicrotubule agents, which block microtubule production, taxol promotes tubulin polymerisation and stabilizes microtubules against depolymerization (Schiff P.B., et al. 1979, Nature 277, 665-667). Microtubules are important subcellular target for chemotherapeutic agents. Antimicrotubule agents, including the Ninca (Catharanthus) alkaloids, are extremely potent, requiring only a few molecules to disrupt the microtubular structure of cancer cells. The discovery of a new compound targeting these structures is of particular importance.
Despite its promise, there is a problem with taxol. This highly fiinctionalised diterpene is isolated from inner bark of relatively rare and slow growing Pacific yew tree Taxus brevifolia, and few related species in extremely small quantities (<0.02% dry wt) (Chemical &Engineering News 1991, (Sept.), 11-18). Himalayan yew, Taxus wallichiana Zucc. is a tree or a large shrub distributed in the north temperate zone of the Indian subcontinent (The Wealth of India (1976), A dictionary of Indian raw materials and industrial products, Vol. X, CSIR publication, New Delhi, P.132-134.). In contrast to the European yew (T. baccata Linn.), the Himalayan yew has a remarkable history of medicinal uses. The leaves of the Himalayan yew are used for treatment of hysteria, epilepsy, nervousness and as a lithic in calculus complaints while its non-poisonous fleshy arils have carminative, expectorant and stomachic properties (The Wealth of India (1976), p.132-134). In addition to the above medicinal properties, Himalayan yew (Taxus wallichiana) also contains the potent anticancer drug taxol and its important precursor 10-deacetyl baccatin III (DAB).
The currently practiced procedures for isolating taxol from bark have the disadvantages of being fatal to the source, being very difficult to carry out, and producing low yields. For example, (Nidensek et al 1990; Journal of Natural Products 53, 1609-1610) a 0.01% yield from a large-scale isolation starting with 806 lbs. or more of Taxus brevifolia bark has been reported. Similar procedures have been reported which comparably produce low yields, ranging from as low as 0.004%, up to about (but not above) 0.017%. A yield of 0.01% translates into 1 g being isolated from 10 kg of the bark, or 1 kg of taxol from 10,000 kg (approx.22,000 lbs) of the bark. A mature tree is said to yield 20-25 lbs. of bark, and this means that nearly 800-1000 trees are needed to produce a kilogram of taxol. Reported yields of taxol from various species of yew tree range from 50 mg/kg to 165 mg/kg (i.e., 0.005- 0.017%). At present, bark of Taxus brevifolia is still being used as the major source of taxol. Because of (a) the low (0.01% or less) yields of taxol from the bark, (b) the relative unavailability of any other useful analogues, and (c) the need to cut the slow-growing trees to harvest the bark, it was decided that the bark was not an attractive source for taxol. Therefore, besides isolation from the bark, there are currently three avenues that are being pursued for the future production of taxol: (1) isolation from renewable plant parts, e.g., the ornamental yew clippings and needles; (2) semi- synthesis of taxol; (3) production of taxol by tissue culture procedures and (4) to find new taxanes from needles which are a renewable source of supply with anticancer properties.
The aim of present invention was to isolate different types of taxanes other than taxol, from the leaves commonly called 'needles' of Taxus wallichiana and evaluate their anticancer potential. In the course of these investigations a taxane brevifoliol [1] was identified which showed promising anticancer activity against in- vitro grown human cancer cell lines. Objects of the invention
The main object of the invention is to provide a composition for the chemotherapeutic treatment of human beings.
It is another object of the invention to provide a method for the chemotherapeutic treatment of human beings using brevifoliol, a taxane isolated from various Taxus species.
It is another object of the invention to provide a method for the treatment of human cancer lines using brevifoliol, a taxane isolated from various Taxus species. Summary of the invention
The present invention provides bioactivity testing of various taxanes isolated from leaves of Himalayan Yew tree Taxus wallichiana against human cancer cell lines grown in- vitro and subsequent identification of brevifoliol [1] as anticancer agent useful in the treatment of various types of cancer such as ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells where the IC90 values are comparatively similar or even less than that of standard drug 'taxol'. Brevifoliol is used as a cancer chemotherapeutic agent.
Accordingly, the present invention provides a composition for chemotherapeutic treatment of human beings, comprising a pharmaceutically effective amount of brevifoliol of the formula 1 and a pharmaceutically acceptable carrier.
In one embodiment of the invention, the amount of brevifoliol is in the range of 0.004 to 20 μg/ml.
The present invention also provides a method for the chemotherapeutic treatment of human beings comprising administering to a patient suffering from cancer, a therapeutically effective amount of brevifoliol of the formula 1
Formula 1 along with a pharmaceutically acceptable carrier.
In one embodiment of the invention, the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
In yet another embodiment of the invention, the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
In yet another embodiment of the invention, the chemotherapeutic treatment is limited to ovarian, colon, breast and oral cancers.
The invention also provides a method for treatment of human cancer lines comprising administering to a patient a therapeutically effective amount of brevifoliol of the formula 1
Formula 1 along with a pharmaceutically acceptable carrier.
In one embodiment of the invention, the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
In yet another embodiment of the invention, the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol. In yet another embodiment of the invention, the human cancer lines are selected from the group consisting of ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells.
The present invention also provides for the use of brevifoliol of the formula 1
Formula 1 along with a pharmaceutically acceptable carrier for the chemotherapeutic treatment of human beings.
In one embodiment of the invention, the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
In yet another embodiment of the invention, the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
In yet another embodiment of the invention, the chemotherapeutic treatment is limited to ovarian, colon, breast and oral cancers.
The invention also provides for the use of brevifoliol of formula 1
Formula 1 along with a pharmaceutically acceptable carrier for chemotherapeutic treatment of human beings.
In one embodiment of the invention, the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
In yet another embodiment of the invention, the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol. In yet another embodiment of the invention, the human cancer lines are selected from the group consisting of ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells. Detailed description of the invention
As a part of the studies on the isolation of anticancer compounds a number of taxanes were isolated from the needles of the plant Taxus wallichiana and tested for their anti-cancer properties against six human cancer cell lines in- vitro. The bioactivity testing was done at two stages. In the initial step, MTT assay was performed from which the inhibitory concentration (IC90) the concentration (μg/mL) of the taxanes required for 90% inhibition of cell growth was deduced. Further, the compounds, which showed cell growth inhibitory activity was evaluated in the clonogenic assay. The MTT assay cannot discriminate between growth inhibition and cell death; it is an overall measurement of cell proliferation (Woerdenbag et al, 1993; J.Nat.Prod. 56 (6): 849-856). Therefore the IC90 data obtained by the MTT assay may overestimate the cell killing activity of a compound. Hence, the clonogenic assay for tumor cells which determines the actual cell death was performed to determine the cytotoxic potential of test compounds. Persons skilled in the art of anti-cancer drug discovery can perform both these assays.
The data obtained in these bioassays against human cancer cells indicated that brevifoliol was highly inhibitory to ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells where the IC90 values were comparatively similar or even less than that of standard drug 'taxol'. Thus brevifoliol can be used as cancer chemotherapeutic agent.
Brevifoliol was first isolated from the leaves (also referred as 'needles') of the plant Taxus brevifolia (Baka et al Phytochemistry 30, p.1613-1614; 1991). The process of its isolation involved extracting the fresh leaves of Taxus wallichiana with ethyl alcohol to get an extract. The crude extract after concentration was diluted with water and partitioned between hexane, chloroform and ethyl acetate sequentially. The chloroform extract upon concentration yielded a dark brown residue. The resultant residue was subjected to column chromatography over silica gel and eluted with chloroform and chloroform-methanol gradient. Six fractions were collected and brevifoliol was isolated from fraction five by rechromatography over silica gel and eluting with hexane-ethyl acetate gradient.
Brevifoliol has been isolated from other species of Taxus including the Himalayan yew tree Taxus wallichiana that is available in India. Recently, the structure of brevifoliol has been revised and it was shown to belong to 11 (15-1) abeo taxoid bicyclic skeleton of formula [1]. For this invention, brevifoliol was also isolated from the leaves of the plant following a process which involved extracting the dried and crushed needles of Taxus wallichiana with methanol for 72 hours and the extract was concentrated in vacuo. The concentrate was diluted with water and extracted with hexane and chloroform respectively. Concentration of the chloroform phase under vacuum left a residue, which was separated by column chromatography over silica gel. Fraction eluted with chloroform-methanol (98:5) contained brevifoliol, which was further purified by rechromatography over silica gel and eluted with chloroform-methanol (99:2). Fractions containing brevifoliol were combined and concentrated and recrystallized from pet-ether and ethyl acetate mixture to get brevifoliol as needles (Chattopadhyay et al (1996) Indian J. Chemistry 35B, 175-177).
The following examples further illustrate the invention and should not be construed as limiting the scope of the invention. EXAMPLES Example-1: In-vitro anticancer MTT assay
The following six human cancer cell lines were procured from the Cell Repository of the National Center for Cell Sciences (NCCS) at Pune. Their corresponding ATCC No. and the organ from which they were isolated are also mentioned in Table 1 below: Table 1: Description of human cancer cell lines and their ATCC Nos.
Cytotoxicity testing in vitro was done by the method of Woerdenbag et al.,1993; J.NatProd. 56 (6): 849-856). 2x103 cells/well were incubated in the 5% CO2 incubator for 24h to enable them to adhere properly to the 96 well polysterene microplate (Grenier, Germany). Test compounds dissolved in 100% DMSO (Merck,Germany) in at least five doses were added and left for 6h after which the compound plus media was replaced with fresh media and the cells were incubated for another 48h in the CO2 incubator at 37°C. The concentration of DMSO used in our experiments never exceeded 1.25%, which was found to be non-toxic to cells. Then, 10 μl MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma M 2128] was added, and plates were incubated at 37°C for 4 h. 100 μl dimethyl sulfoxide (DMSO, Merck, Germany) were added to all wells and mixed thoroughly to dissolve the dark blue crystals. After a few minutes at room temperature to ensure that all crystals were dissolved, the plates were read on a SpectraMax 190 Microplate Elisa reader (Molecular Devices Inc., USA), at 570 nm. Plates were normally read within 1 h of adding the DMSO. The experiment was done in triplicate and the inhibitory concentration (IC) values were calculated as follows: % inhibition =[l-OD (570 nm) of sample well / OD (570 nm) of control well] x 100. IC90 is the concentration μg/mL required for 90% inhibition of cell growth as compared to that of untreated control. The results described in Table 2 indicate that brevifoliol is active against all cancer cell lines except liver cancer (WRL-68). Table 2: Cytotoxic properties (IC 90 in μg/mL) of various taxanes isolated from T.wallichiana against human cancer cells.
Example-2: Soft Agar Assay For Colony Formation
The clonogenic assay for tumor cells which determines the actual cell death was performed to determine the cytotoxic potential of test compounds. The principle of clonogenic assay is to investigate the ability of an individual cell to form a colony on a soft agar plate containing various concentrations of test compounds.
Cells not able to form colonies are considered clonogenically dead (Beekman et al 1997; J.NatProd. 60(4): 325-330). The concentration of test compound resulting in 90 % of the control (untreated) colonies was denoted as IC90 and was used as a parameter for cytotoxicity. The assay was performed as described previously except that the test compounds were added into the top soft agar and the cells were plated out to form colonies. Anthracycline derivative doxorubiciti and microtubule depolymerization inhibitor paclitaxel (Sigma Chem. Co., St. Loius, USA) both established anticancer agents were included as standard reference drugs.
Table 3: Cytotoxic properties (IC 90 in μg/mL) of various taxanes isolated from T.wallichiana against human cancer cells.
Example 3: Chemical Process for the Isolation of Brevifoliol
Dried and crushed needles of Taxus wallichiana (1 kg) were extracted with methanol (3x3 L) for 72 hours and concentrated in vacuo. The concentrate was diluted with water and extracted with hexane (1L) and chloroform (1L) respectively. Concentration of the chloroform phase under vacuum left a residue (12g), which was separated by column chromatography over silica gel. Fraction eluted with chloroform-methanol (95:5) contained brevifoliol, which was further purified by re-chromatography over silica gel and eluted with chloroform-methanol (98:2). Fractions containing brevifoliol were concentrated under vacuum and brevifoliol was obtained as amorphous solids, (50 mg).
Brevifoliol was crystallized from petroleum ether-acetone mixture as needles. Brevifoliol, mp 200-201°C, ]D -25°C (C 1, MeOH) was characterized on the basis of its reported spectral data and by direct comparison with an authentic sample (Chattopadhyay, S.K. et al , Indian J. Chemistry 35B, 175-177 (1996)). The reaction mechanism is given below:
MeOH
Crushed needles ► MeOH ext. Hexane/H20
H20 (discarded)
CHCI3
CHCI3 H20 (Discarded)
SiOa/ CHCI3-MeOH (95:5)
Brevifoliol rich fraction
Rechromatography SKV CHCI3-MeOH (98:2) Brevifoliol

Claims

We claim:
1. A pharmaceutical composition for the chemotherapeutic treatment of human beings comprising a therapeutically effective amount of brevifoliol of formula 1
Formula 1 along with a pharmaceutically acceptable carrier.
2. A composition as claimed in claim 1 wherein the concentration of brevifoUol is in the range of 0.004 to 20 μg/ml.
3. A method for the chemotherapeutic treatment of human beings comprising administering to a cancer patient, a therapeutically effective amount of brevifoliol of formula 1
Formula 1 along with a pharmaceutically acceptable carrier.
4. A method as claimed in claim 3 wherein the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
5. A method as claimed in claim 3 wherein the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
6. A method as claimed in claim 3 wherein the chemotherapeutic treatment is limited to ovarian, colon, breast and oral cancers.
7. A method as for treatment of human cancer lines comprising administering to a patient a therapeutically effective amount of brevifoliol of the formula 1
along with a pharmaceutically acceptable carrier.
8. A method as claimed in claim 7 wherein the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
9. A method as claimed in claim 7 wherein the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
10. A method as claimed in claim 7 wherein the human cancer lines are selected from the group consisting of ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells.
11. Use of brevifoliol of the formula 1
Formula 1 along with a pharmaceutically acceptable carrier for the chemotherapeutic treatment of human beings.
12. Use as claimed in claim 11 wherein the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
13. Use as claimed in claim 11 wherein the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
14. Use as claimed in claim 11 wherein the chemotherapeutic treatment is limited to ovarian, colon, breast and oral cancers.
15. Use of brevifoliol of formula 1
Formula 1 along with a pharmaceutically acceptable carrier for chemotherapeutic treatment of human cancer lines selected from the group consisting of ovarian (PA-1), colon (Caco-2), breast (MCF-7) and oral (KB-403) cancer cells.
16. Use as claimed in claim 15 wherein the concentration of brevifoliol is in the range of 0.004 to 20 μg/ml.
17. Use as claimed in claim 15 wherein the pharmaceutically acceptable carrier does not interfere with the activity of brevifoliol.
EP02781652A 2002-12-16 2002-12-16 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings Withdrawn EP1572191A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2002/005399 WO2004054569A1 (en) 2002-12-16 2002-12-16 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings

Publications (1)

Publication Number Publication Date
EP1572191A1 true EP1572191A1 (en) 2005-09-14

Family

ID=34362306

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02781652A Withdrawn EP1572191A1 (en) 2002-12-16 2002-12-16 Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings

Country Status (2)

Country Link
EP (1) EP1572191A1 (en)
AU (1) AU2002348815A1 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004054569A1 *

Also Published As

Publication number Publication date
AU2002348815A1 (en) 2004-07-09

Similar Documents

Publication Publication Date Title
US7196115B2 (en) Pharmaceutical composition containing brevifoliol for use in chemotherapeutic treatment of human beings, method therefor
RU2129551C1 (en) 4,10-DIACETATE-2-BENZOATE OF 5β,20-EPOXY-1,2α,4,7β,- -10β,13α-HEXAHYDROXYTAX-11-ENE-9-ONE CONTAINING ESTER GROUP AT POSITION 13 FORMED BY (2R,2S)-N-HEXANOYL-3-PHENYL- -ISOSERINE, METHOD OF ITS PREPARING AND PHARMACEUTICAL COMPOSITION
JP2929025B2 (en) Macrocyclic lactones that inhibit cell growth
US9562059B2 (en) Anticancer maytansinoids with two fused macrocyclic rings
Appendino Ingenane diterpenoids
WO2003047508A2 (en) Paclitaxel solvates
JPH0665675B2 (en) Novel bryostatin 4-8
JP3430322B2 (en) Spongistatin 5, 7, 8 and 9
Zhao et al. Six new eremophilane derivatives from two Ligularia species
JPH11507636A (en) Novel cryptophysin
Chattopadhyay et al. Taxoid from the needles of the Himalayan yew Taxus wallichiana with cytotoxic and immunomodulatory activities
Zhou et al. Spiroamentotaxols A–D: unprecedented 6/6/6/5/6/6/6/6 spiro-octacyclic bis-diterpene heterodimers from the endangered conifer Amentotaxus yunnanensis and their bioactivities
Logrado et al. Synthesis and biological evaluation of new salicylate macrolactones from anacardic acids
De Souza (+)‐Discodermolide: A Marine Natural Product Against Cancer
AU2005338556B2 (en) Novel loganin analogues and a process for the preparation thereof
WO1998049895A1 (en) Selectively cytotoxic acetogenin compounds
Lixin et al. Antitumor and immune regulation activities of the extracts of some Chinese marine invertebrates
AU7543198A (en) Pharmaceutical composition containing uscharidin or its analogues
US5962515A (en) Process for isolation and synthesis of 1-(3,4 methylenedioxy-phenyl)-1E-tetradecene and its analogues and their activities against tumors and infections
Yoder Isolation and structure elucidation of cytotoxic natural products from the rainforests of Madagascar and Suriname
Mohammed et al. Cytotoxic Activity of New Tropinene Glycoside Isolated from Solandra grandiflora Sw.
Martínez et al. Synthesis and conformational analysis of leptocarpin derivatives: Influence of modification of the oxirane ringon leptocarpin'S cytotoxic activity
WO2001034589A1 (en) Semi-synthesis of baccatin iii from 9-dihydro-13-acetylbaccatin iii
US6458831B1 (en) Use of two plant phenols in the treatment of arteriosclerosis
Appendino 1 Naturally occurring taxoids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050621

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO

17Q First examination report despatched

Effective date: 20061031

17Q First examination report despatched

Effective date: 20061031

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080701